These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26578725)

  • 21. Vemurafenib-induced bilateral facial palsy.
    Shailesh FN; Singh M; Tiwari U; Hutchins LF
    J Postgrad Med; 2014; 60(2):187-8. PubMed ID: 24823520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
    Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
    J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapidly metastasizing malignant melanoma characterized by a rare BRAF mutation not responding to vemurafenib.
    Starz H; Gutschi M; Welzel J; Haas C
    J Dtsch Dermatol Ges; 2014 Feb; 12(2):151-4. PubMed ID: 24238398
    [No Abstract]   [Full Text] [Related]  

  • 24. Dermatological approach to vemurafenib skin toxicity: a single centre experience.
    Fava P; Marra E; Astrua C; Brizio M; Cavaliere G; Quaglino P; Fierro MT; Savoia P
    G Ital Dermatol Venereol; 2016 Feb; 151(1):25-31. PubMed ID: 25296968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
    van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
    J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
    [No Abstract]   [Full Text] [Related]  

  • 26. Targeting BRAFV600E in an inducible murine model of melanoma.
    Hooijkaas AI; Gadiot J; van der Valk M; Mooi WJ; Blank CU
    Am J Pathol; 2012 Sep; 181(3):785-94. PubMed ID: 22796458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
    Trunzer K; Pavlick AC; Schuchter L; Gonzalez R; McArthur GA; Hutson TE; Moschos SJ; Flaherty KT; Kim KB; Weber JS; Hersey P; Long GV; Lawrence D; Ott PA; Amaravadi RK; Lewis KD; Puzanov I; Lo RS; Koehler A; Kockx M; Spleiss O; Schell-Steven A; Gilbert HN; Cockey L; Bollag G; Lee RJ; Joe AK; Sosman JA; Ribas A
    J Clin Oncol; 2013 May; 31(14):1767-74. PubMed ID: 23569304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Concerns regarding BRAF testing algorithm.
    Clark RR; Garioch JJ; Moncrieff MD
    Br J Dermatol; 2013 Nov; 169(5):1167-8. PubMed ID: 23855527
    [No Abstract]   [Full Text] [Related]  

  • 29. Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.
    Keating GM
    Drugs; 2016 Apr; 76(5):605-15. PubMed ID: 26984388
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epidermotropic progression of melanoma during therapy with vemurafenib and trametinib.
    Ferrara G; Cacitti V; Improta G; Lo Re G; Corradin MT
    J Am Acad Dermatol; 2016 Oct; 75(4):e133-e135. PubMed ID: 27646754
    [No Abstract]   [Full Text] [Related]  

  • 31. Oncogenic RAF: a brief history of time.
    Solit D; Rosen N
    Pigment Cell Melanoma Res; 2010 Dec; 23(6):760-2. PubMed ID: 20973931
    [No Abstract]   [Full Text] [Related]  

  • 32. Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma.
    Koop A; Satzger I; Alter M; Kapp A; Hauschild A; Gutzmer R
    Br J Dermatol; 2014 Jan; 170(1):220-2. PubMed ID: 24032672
    [No Abstract]   [Full Text] [Related]  

  • 33. Nonmalignant cutaneous findings associated with vemurafenib.
    Sukhnandan F; Kahn MR; Bhattacharjee P
    Cutis; 2018 Jan; 101(1):E2-E4. PubMed ID: 29529120
    [No Abstract]   [Full Text] [Related]  

  • 34. Relationship between vemurafenib plasma concentrations and survival outcomes in patients with advanced melanoma.
    Kichenadasse G; Hughes JH; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):615-620. PubMed ID: 31786653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dramatic response to radiotherapy combined with vemurafenib. Is vemurafenib a radiosensitizer?
    Baroudjian B; Boussemart L; Routier E; Dreno B; Tao Y; Deutsch E; Blanchard P; Dhermain F; Vilcot L; Vagner S; Eggermont A; Mateus C; Robert C
    Eur J Dermatol; 2014; 24(2):265-7. PubMed ID: 24721778
    [No Abstract]   [Full Text] [Related]  

  • 36. A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.
    Maleka A; Åström G; Byström P; Ullenhag GJ
    BMC Cancer; 2016 Aug; 16():634. PubMed ID: 27520988
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
    Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
    Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful management of life-threatening disseminated intravascular coagulopathy due to metastatic melanoma.
    Bhattacharyya A; Cooper A; Hong A; Iland H; McNeil C
    Intern Med J; 2014 Feb; 44(2):207-8. PubMed ID: 24528820
    [No Abstract]   [Full Text] [Related]  

  • 39. A Pilot Trial of the Combination of Vemurafenib with Adoptive Cell Therapy in Patients with Metastatic Melanoma.
    Deniger DC; Kwong ML; Pasetto A; Dudley ME; Wunderlich JR; Langhan MM; Lee CR; Rosenberg SA
    Clin Cancer Res; 2017 Jan; 23(2):351-362. PubMed ID: 28093487
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.